MarginsXMarginsX
Home › Markets › Health Care › TENX

Tenax Therapeutics Inc. (TENX)

TENX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.48
-8.64% on the day
Market cap
$67.4M
Micro cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$52.6M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/34956/000119312526099393/0001193125-26-099393-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTENX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000034956
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$52.6M
Operating income-$56.4M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$97.6M
Total assets$104.2M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
27.6 months
$113.7M cash at September 30, 2026
Share count, 1 year
+629.3%
2025-11-11 to 2026-10-31 · +15166.3% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$5.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$113.7M cash; operating cash flow -$12.3M a quarter.Report 2026-09-30
Shares outstanding45,536,448 (2026-10-31); 6,243,575 a year earlier; 23,862,434 three years earlier. 3y figure adjusted for splits (1-for-80 overall).Cover page 2026-10-31
Reverse splits, 3 years1; latest 1-for-80 on 2024-01-03Source 2024-01-03
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-03-24
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCherry Bekaert LLP, Raleigh, North Carolina, United StatesPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $5.1M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$16.7M-$12.5M$113.7MNo debt tags$010-Q 2026-11-05
Q2 2026
2026-06-30
$0-$17.8M-$14.2M$118.0MNo debt tags$010-Q 2026-07-31
Q1 2026
2026-03-31
$0-$15.7M-$9.3M$118.8MNo debt tags$010-Q 2026-05-12
Q4 2025
2025-12-31
$0-$15.5M-$13.4M$97.6MNo debt tags$010-K 2026-03-10
Q3 2025
2025-09-30
$0-$15.8M-$9.2M$99.4MNo debt tagsNeeds four quarters10-Q 2025-11-12
Q2 2025
2025-06-30
$0-$10.8M-$6.3M$105.5MNo debt tagsNeeds four quarters10-Q 2025-08-13
Q1 2025
2025-03-31
$0-$10.4M-$7.0M$111.4MNo debt tagsNeeds four quarters10-Q 2025-05-14
Q4 2024
2024-12-31
Not filed-$6.3M-$3.5M$94.9M$0$010-K 2026-03-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM S-3
S-32026-03-24
Latest annual report10-K2026-03-10
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-22

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.1%
1 month+1.2%
3 months-11.5%
Year to date-86.7%
1 year-75.8%
From 52-week high-91.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
GOSSGossamer Bio Inc.$10.98+0.09%$67.2M
ZYBTZhengye Biotechnology Holding Limited$1.43-4.67%$67.8M
MNOVMedicinova Inc$1.34-3.94%$68.7M
CRBPCorbus Pharmaceuticals Holdings Inc.$3.38-0.44%$69.5M
COYACoya Therapeutics Inc.$3.00-4.15%$70.4M
VTVTvTv Therapeutics Inc.$17.69-10.16%$71.0M
ACRVAcrivon Therapeutics Inc.$1.46+0.69%$62.6M
MAIAMAIA Biotechnology Inc.$1.01+1.00%$62.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier